The OpGen Gene Panel product tests for causes of antimicrobial and antibiotic resistance in hospital patients. The FDA approval, CEO Oliver Schacht said, will help it move away from research and ...
San Francisco, USA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The Pan-Genomic and Multi-Gene Panel Testing Market reached a valuation of US$ 8,907.34 million in 2024 and is projected to grow steadily over the ...
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center Of the 582 surveys sent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results